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Core symptoms of depression in diagnostic
classification systems and rating scales
espite intensive biologically oriented psychiatric
research over the last decades,the anatomical and physi-
ological basis of depression is still far from being com-
pletely understood.Besides psychological and social fac-
tors,biological variables which lead to a generally disturbed
central nervous homeostasis apparently play a major role.
The so-called catecholamine- and serotonin-deficiency
hypothesis,
1 which postulates a deficiency of monoamines
(noradrenalin and serotonin) within the synaptic cleft,plays
a major role in the understanding of the pathophysiology
of depression. In addition, Major Depressive Disorder
(MDD) most likely involves the limbic structures (in cir-
cuits involving the cingulate-hippocampus-mamillary bod-
ies-anterior thalamus-cingulate),reward circuits (nucleus
accumbens,sublenticular extended amygdala,amygdala,
ventral tegmentum, cingulate, insula, thalamus, parahip-
pocampal gyrus,and prefrontal cortex),hypothalamus,and
anterior temporal cortex.
2 Both deficiencies of neuro-
transmitters involved in these circuitries,as well as damage
to neurons and loss of connectivity,eg,by enduring hyper-
cortisolemia,can be the underlying substrate for what man-
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Core symptoms of depression are a combination of psy-
chological and somatic symptoms, often combined with
psychomotor and cognitive disturbances. Diagnostic clas-
sification of depression including the concepts of melan-
cholic, endogenous, or severe depression describe severely
depressed patients suffering from most of the core symp-
toms, together with clinical characteristics of a cyclic
unipolar or bipolar course, lower placebo response rates,
higher response rates to electroconvulsive therapy, to anti-
depressant treatments with dually or mixed modes of
action, or to lithium augmentation. Higher rates of hypo-
thalamic-pituitary-adrenal axis hyperactivity and specific
electroencephalographic patterns have also been shown
in this patient group. Summarizing the symptomatology
of depression in these patients, a broad overlap between
the abovementioned subgroups can be suggested.
Because the positive diagnosis of those core symptoms of
depression may include clinical consequences, it would be
of use to integrate all the mentioned concepts in the
upcoming new versions of the diagnostic systems DSM-V
and ICD-11.
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:309-320.ifests clinically as depression.Consequently,influence on
neurotrophic factors is also thought to be one possible
mechanism of action of antidepressant treatments.
3-6 In
addition,a major disturbance of the circadian timing sys-
tem in depression has been discussed.
7
Depressive syndromes responsive to specific antidepres-
sant therapies are classified within diagnostic entities
using operationalized diagnostic systems such as the
American Psychiatric Association's Diagnostic and
Statistical Manual of Mental Disorders. 4th ed, Text
Revision (DSM-IV-TR)
8 or the The ICD-10 Classification
of Mental and Behavioral Disorders (ICD-10).
9 Using
these diagnostic systems,depressive disorders are char-
acterized by a variety of symptoms,as shown in Table I.
To diagnose MDD according to ICD-10,a minimum of
two main symptoms and two accessory symptoms have
to be present (Table II,adapted from Bauer et al
11).
According to DSM-IV-TR,five of the nine main criteria
of depression have to be present for a diagnosis of an
episode of a MDD.This term is often used synonymously
with unipolar depression to distinguish it from a major
depressive episode as part of bipolar disorder.
The first DSM-IV-TR core symptom is depressed mood
during most of the day.This can be expressed by sadness,
but may also be expressed as a feeling of emptiness or,in
children or adolescents,as irritable mood.This draws a
clear distinction between depression and grief or
bereavement (characterized in DSM-IV-TR,V62.82).As
with the other core symptoms, this symptom counts
towards the diagnosis of depression if it is indicated by
patient report or observation.The other psychological
core symptoms are:markedly diminished interest or plea-
sure in all or almost all activities,fatigue or loss of energy
every day,and disorders of thought and thinking (both
the formal aspects of thinking and the ability to concen-
trate and make decisions,as well as the content which is
often characterized by feelings of worthlessness or inap-
propriate guilt),perhaps combined with hopelessness and
recurrent suicidal thoughts.DSM-IV-TR also mentions
three somatic or behavioral core symptoms:significant
weight loss or decrease in appetite, insomnia or hypo-
somnia,and psychomotor agitation or retardation.
Subsyndromal depression,eg,often presented by elderly
patients,does not fulfill the complete diagnostic criteria
according to DSM-IV-TR or ICD-10,but might neverthe-
less necessitate often antidepressant therapy.In addition,
differences in the clinical picture of depressive disorders
influence both the choice of specific antidepressant ther-
apies and the probability that antidepressant treatment
will be successful. Sometimes also the fact that patients
stop eating and lose weight may change the clinical picture
of depressive disorders.
In addition to the criteria for depressive disorder included
in the DSM-IV-TR and the ICD-10,traditionally used sub-
types were at least partially still of relevance,and some are
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Selected abbreviations and acronyms
MDD Major Depressive Disorder
DSM Diagnostic and Statistical Manual of Mental
Disorders
ICD International Classification of Diseases
HAM-D Hamilton Depression Rating Scale
SSRI selective serotonin reuptake inhibitor
ECT electroconvulsive therapy
Category of depressive  Symptom list
symptoms
Affective symptoms • Depressed mood
• Anhedonia
• Anxiety
Psychomotor disturbances • Retardation
• Agitation
• Loss of energy and activity
Disturbances of cognition  • Feelings of guilt
and memory • Feelings of worthlessness
• Mood-congruent and 
-incongruent delusions
• Concentration deficits
• Memory deficits
Psychovegetative disturbances  • Sleep disturbances (insom-
and somatic complaints nia, early-morning awakening)
• Diurnal changes
• Loss of appetite and weight
• Sexual dysfunction
• Constipation
• Pain syndromes
• Hypertonia
• Tachycardia
Biological signs • Hypercortisolemia
• Abnormal thyroid function tests
• Sleep EEG abnormalities
• Hippocampal atrophy
• Genetic risk factors
• Enhanced cardiovascular risk
Table I. Symptomatology of depressive disorders.
8-10 EEG, electroen-
cephalogramdescribed in DSM and ICD concepts,eg,of endogenous
vs reactive or neurotic depression,
12 melancholic vs non-
melancholic depression,
13 or psychotic vs nonpsychotic
depression.
13These traditional concepts underline the huge
heterogeneity of patients suffering from depressive disor-
der,which might be overseen if only the diagnosis of the
global category “depressive disorder”is used.Using the
additional subtyping,the treating physician or psychiatrist
might be enabled to specifically choose the best treatment
option for an individual patient with the highest response
probability and the most convenient clinical course for the
patients.
It was therefore postulated that symptomatic classifica-
tions beyond DSM and ICD may be a necessary diag-
nostic basis to select more specific treatment options,
considerably enhancing response quotes to antidepres-
sant treatments.
12-14 In patients suffering from depression
with melancholic features, a variety of authors have
described a greater illness severity,
15 greater relevance of
genetic determinants,differential altered biological func-
tioning,especially of the hypothalamic-pituitary-adrenal
(HPA) axis,together with a superior response to physi-
cal treatments such as antidepressants and electrocon-
vulsive therapy (ECT) and,in addition,a lower placebo
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DSM-IV ICD-10
Major depressive disorder A. Depressive episode (F32)
A. single episode (296.2x) B. Recurrent depressive disorder (F33)
B. recurrent (296.3x) Severity:
• mild (F--.0): at least 2 main symptoms, plus at least 2 accessory 
symptoms; none of the symptoms intense
• moderate (F--.1): at least 2 main symptoms, plus at least 3  
accessory symptoms; some symptoms marked
• severe (F--.2): all 3 main symptoms, plus at least 4 accessory 
symptoms; some symptoms severe with intensity
Criteria major depressive episode (abridged): Criteria of depressive episode (abridged):
A Over the last 2 weeks, 5 of the following features should be  Minimum duration of episode: about 2 weeks
present most of the day, or nearly every day (must include 1 or 2): Main symptoms:
1. depressed mood 1. depressed mood
2. loss of interest or pleasure in almost all activities 2. loss of interest and enjoyment
3. significant weight loss or gain (more than 5% change in 1 month)  3. reduced energy, increased fatigability
or an increase or decrease in appetite nearly every day Accessory symptoms:
4. insomnia or hypersomnia 1. reduced concentration and attention
5. psychomotor agitation or retardation (observable by others) 2. reduced self-esteem and self-confidence
6. fatigue or loss of energy 3. ideas of guilt and unworthiness
7. feelings of worthlessness or excessive or inappropriate guilt  4. agitation or retardation
(not merely self-reproach about being sick) 5. ideas or acts of self-harm or suicide
8. diminished ability to think or concentrate, or indecisiveness  6. sleep disturbances
(either by subjective account or as observed by others) 10. loss of appetite.
9. recurrent thoughts of death (not just fear of dying), or 
recurrent suicidal ideation, or a suicide attempt, or a specific 
plan for committing suicide.
B The symptoms cause clinically significant distress or impairment in 
social, occupational, or other important areas of functioning.
C The symptoms are not due to a physical/organic factor or illness
D The symptoms are not better explained by bereavement (although 
this can be complicated by major depression).
Table II. Classification and criteria of major depressive disorder (DSM-IV-TR)
8 and depressive episode (ICD-10).
9
Table adapted from ref 11: Bauer M, Whybrow PC, Angst J, Versiani M, Möller H-J, WFSBP Task Force on Tretment Guidelines for Unipolar Depressive Disorders.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of unipolar depressive disorder. Part 1: Acute and continu-
ation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3:4-43. Copyright © WFSBP 2002response rate.
14Therefore the use of a diagnostic system
detecting predominantly the core symptoms of melan-
cholic depressive disorders (CORE system, Table III)
was suggested.
14
Atypical depression including predominantly an increase
in appetite and weight gain together with hypersomnia
(Table IV) seems to be located at the other end of the
spectrum. Patients suffering from atypical depression
show not only a specific clinical picture including pecu-
liarities regarding the symptomatology and the clinical
course of the disease,
16 but also a differential response
pattern to specific antidepressants.
17
A completely different approach is the analysis of
depression rating scales such as the Hamilton Depression
Rating Scale (HAM-D)
18 using multidimensional scaling
procedures.
19A distinction between primary components
of depression,which are related directly to core symp-
toms of major depression, secondary components
focused on dysthymic disorders and components related
to more accessory symptoms has been made.
19 On the
basis of probabilistic test models 6 out of 17 items of the
HAM-D17 scale (Table V) were classified as a melan-
cholia subscale suitable for quantitative comparisons;the
original HAM-D17 scale was considered to be without
adequate consistency during treatment course with
andidepressant medication.
20
The factor-analytic approach confirmed that solely the
abovementioned items of the HAM-D scale can be com-
bined as a valid indicator for the severity of depression.
19
This was confirmed in a recently published paper ana-
lyzing a randomized controlled trial (RCT) comparing
the treatment of depression with hypericum perforatum
extract vs placebo.
21 It was concluded that the HAM-D6
subscale should be used as a primary outcome measure
in antidepressant trials rather than the HAM-D17 scale.
In addition to the described symptomatology predomi-
nantly distinguishing between core symptoms of depres-
sion including melancholic features and other symptoms,
depressive syndromes can be subdivided clinically accord-
ing to the clinical course (unipolar and bipolar depression),
the clinical severity of depression (eg, measured using
depression rating scales or subdividing in in- and outpa-
tients), the clinical symptomatology (eg, psychotic vs
nonpsychotic depression,retardation,catatonic symptoms)
and specific subgroups of depressed patients (eg,atypical
depression).Some scientific evidence from RCTs and clin-
ical evidence derived from broad clinical experience and
consensus showed differential response to different anti-
depressant treatment options.Therefore,specific clinical
recommendations for subgroups of depressed patients are
described in the following sections.
Clinical subtypes of depressive disorders 
and effectiveness of antidepressant 
treatment options
Influence of core symptoms and the severity of the 
disease on treatment outcome
Melancholic depression
According to DSM-IV-TR,melancholic features are char-
acterized by a loss of the ability to feel pleasure and a vari-
ety of somatic symptoms (Table I) and psychomotor alter-
ations. Other authors conceptualized melancholia as a
categorical entity within a variety of different subgroups of
depressive disorder,
14 leading to a clinical syndrome includ-
ing specific psychopathological characteristics (Table III),
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• Mood state items
(eg, guilt, remorse and self-reproach, feelings of unworthiness and 
hopelessness, greater severity of mood disturbances, non-reactivity 
of mood, loss of interest, anhedonia, greater suicidal ideation)
• Vegetative items
(eg, loss of appetite and/or weight loss, (terminal) insomnia, 
diurmal variation with mood, energy worse in the morning )
• Other features
(eg, retardation, agitation, concentration difficulties, psychotic 
features)
Table III. “CORE” Symptoms of Depression.
14
• Depressed mood
• Guilt
• Work and interests
• Retardation
• Psychic anxiety
• General somatic symptoms
Table IV. HAM-D6 melancholic subscale.
20
• Increase in appetite and weight gain 
• Hypersomnia
• Leaden paralysis
• Long-standing pattern of interpersonal rejection sensitivity
Table V. Atypical depression according to DSM-IV.
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together with a greater overall severity of disease,episodic
courses of the illness,a positive family history for depres-
sion,the lack of high comorbidity with DSM-IV-TR axis 1
and axis 2 disorders and a high rate of biological abnor-
malities including HPA axis hyperactivity.
13,14,22 In addition,
a low likelihood of placebo response together with high
responsiveness to tricyclic antidepressants (TCA),lithium
augmentation and ECT was postulated.
13,14 Also lower
response rates to psychotherapeutic approaches were
described.
23 Nevertheless, data supporting this view are
derived predominantly from subgroup analyses of clinical
trials and clinical observations.Up to now,head-to-head
comparisons of different antidepressant classes in melan-
cholic and nonmelancholic depression are lacking.
23
Therapeutic consequences of the presence of melancholic
features are therefore very similar to that for severe depres-
sion,described more in detail in the next section.It can be
summarized that electroconvulsive therapy (ECT),dually
acting antidepressants,and lithium augmentation in case of
nonresponse can be recommended for patients suffering
from melancholia.
Severity of the disease
Depressive episodes can be classified as mild,moderate,
or severe depressive disorder (according to ICD-10).
Subsyndromal depression may enhance the risk of devel-
oping a syndromal depressive disorder according to ICD-
10 or DSM-IV-TR requiring antidepressant treatment.
Besides the clinical judgment,eg,using the diagnostic cri-
teria according to ICD-10 or to the Clinical Global
Impression scale (CGI-S, Item I, severity of disease),
24
severity groups can be separated using depression rating
scales such as the HAM-D18 or the Montgomery-Åsberg
Rating Scale for Depression (MADRS).
25 Patients suf-
fering from severe depression,for example,reach a score
of at least 25 on the HAM-D17 scale
26 or 30 on the
MADRS.
27The subdivision according to the severity of
depression is of clinical importance because for example,
the NICE (National Institute for Clinical Excellence)
guidelines
28 recommend antidepressant treatments in pri-
mary care in moderate and severe,but not mild,depres-
sion.For patients suffering from mild depression,NICE
recommends “watchful observation” or psychological
intervention as first-line treatment,and antidepressants
only in the case of refractoriness.
28
In moderate depression,nonbiological treatments are also
the first choice in some guidelines although,in reality,most
moderately depressed patients do require additional anti-
depressant medication. Furthermore, there is a distinct
probability of response using phytotherapeutics such as
hypericum perforatum (St Johns wort)
29-32 or benzodi-
azepines without antidepressants (even if this option is not
recommended due to their potential for causing depen-
dency and addiction)
33 only in people with mild-to-mod-
erate depression. Moreover, it has been suggested that
drug-placebo differences after treatment with antidepres-
sant medication are relatively small and increase as a func-
tion of baseline severity of depression.
34 However,accord-
ing to other reports about the effectiveness of
antidepressants,eg,duloxetine
35 or fluoxetine,
36 in mild-to-
moderate depression,the treatment of those subgroups of
depressed patients also has been recommended.
37
Nevertheless,there is some evidence that especially severe
depressive syndromes show a better response to ECT,to
tTCAs
38 (TCA) and to dually acting substances
39 such as
venlafaxine, duloxetine, or mirtazapine. Especially in
severely depressed and hospitalized patients,mixed sero-
tonergic and noradrenergic TCAs compared favorably
with selective serotonin reuptake inhibitors (SSRIs)
38,40 and
the reversible monoamine oxidase-A inhibitor (RIMA)
moclobemide
41 However, escitalopram has also shown
good results in severe depression
42 (Montgomery et al,
unpublished data).Summarizing published study results
of recent years,in spite of the discouraging meta-analytic
results of Kirsch et al,
43 it has to be stated that there is an
overall worldwide consensus that antidepressants are effi-
cacious in the treatment of depression,regardless of the
severity of the disease.
44
Depression with psychotic symptoms
Psychotic features of depression such as hallucinations
or delusions,eg,delusional hypochondria,feelings of guilt
or nihilistic thoughts,are predominantly mood-congru-
ent, but may also be noncongruent to the depressed
mood.Depressive episodes with psychotic symptoms are
in most cases an indicator of particular severity of the dis-
ease,including a high suicide risk.This additional risk fac-
tor has to be taken into account in planning treatment.
In patients suffering from psychotic symptoms,usually a
combination of the antidepressant therapy with antipsy-
chotic medication is recommended,
45 although it has been
reported that there are no advantages of such a combi-
nation in specific patient subgroups, eg, in elderly
patients.
46TCAs and selective SSRIs in combination withantipsychotics are recommended,and amoxapine treat-
ment has shown somewhat lower, but also significant,
efficacy.
47,48 In addition,a few reports about good efficacy
of SSRI monotherapy during acute and maintenance
treatment have been published.
49,50 ECT has been rec-
ommended as a possible first-line treatment in such cases
because of its high effectiveness during acute-treatment
51
and a more favorable long-term outcome
52 in this sub-
group of patients, especially in comparison with phar-
macotherapy.
53 In addition,early consideration of lithium
augmentation is recommended,especially in this patient
group in case of antidepressant treatment failures.
54,55
Psychomotor agitation and retardation
Severe psychomotor retardation,stupor,immobility,and,
in contrast,severe agitation (labeled by some authors as
catatonic features of depression), can also be seen in
depressed patients.
56-58 A relatively high overlap with
patients suffering from melancholic and severe depression
has been suggested.
13,22 ECT has been reported to have an
excellent clinical effectiveness in these cases,
59,60 as well as
the administration of benzodiazepines (lorazepam) dur-
ing the acute-phase treatment,which can lead to immedi-
ate relief of catatonic symptoms.In routine clinical use,
sedating antidepressants or combinations of nonsedating
antidepressants with sedating benzodiazepines are used in
agitated patients,whereas activating substances such as
SSRIs or noradrenalin reuptake inhibitors (NARIs) are
used in patients with predominant psychomotor inhibition.
Influence of course-related aspects on treatment 
recommendations
Unipolar depression 
A significant proportion of depressive disorders show an
episodic course.With the exception of the recurrent brief
depressive episodes singled out in the ICD-10,the thresh-
old for reaching a diagnosis is that symptoms are present
for at least 2 weeks.Shorter duration places the episodes
into a “subthreshold” group.The differences between
threshold and subthreshold depression is feasible but not
very helpful in clinical work,since it has been shown that
also subthreshold depression causes disability and often
requires treatment.In particular,depressive disorders in
children and adolescents,as well as depression in old age,
comprise a variety of inherent diagnostic problems. In
addition,these problems may furthermore be aggravated
by specific comorbidities such as anxiety or personality
disorders.In the case of the first diagnosis of depression
and without knowledge about the future time course of
depression, primary unipolar depressive episodes and
depressive syndromes showing bipolar features in the
future cannot be distinguished clinically.Some authors
even postulate that the distinction between unipolar and
bipolar depression in modern diagnostic systems may
have no clinical relevance for the acute treatment,
13 but
of course as described in the following specific risks
(switch) of bipolar depression should lead to a modifica-
tion of the acute treatment to prevent triggering of manic
episodes.
Bipolar depression
Diagnostic criteria for a depressive episode due to bipo-
lar-I disorder are the same as described already for the
case of unipolar depression (Table II). In addition, to
diagnose a bipolar disorder,there should have been pre-
viously at least one manic or mixed episode including a
period of abnormally and persistently elevated,expan-
sive, or irritable mood lasting at least 1 week (or even
shorter,if hospitalization is necessary).During this time
period,grandiosity or inflated self-esteem are normally
present,together with decreased need for sleep,hyper-
activity, psychomotor agitation, racing thoughts with
flight of ideas,distractibility,and a pressure to keep talk-
ing causing marked impairment in social functioning.In
case of a mixed episode,these symptoms together with
depressive symptoms are present at the same time for at
least 1 week.In case of bipolar-II disorder,at least one
episode of hypomania,a period of manic symptoms of
lesser severity which last at least 2 to 4 days, has been
present in the patients´ history.However,shorter hypo-
manic episodes may also justify treating a patient accord-
ing to standards for bipolar depression, not unipolar
depression.
61,62 In addition,a continuity between bipolar-
II disorder and unipolar severe (major) depression has
been suggested.
63
Because bipolar depression has the same symptoms as
unipolar depression and at the time of the first depres-
sive episode this information is not yet available,up to
50% of younger patients suffering from depression as the
first index episode later receive the diagnosis of a bipo-
lar disorder,
64,65 but these rates remain controversial.
66
Although the evidence for efficacy and effectiveness of
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than the evidence for the treatment of unipolar depres-
sion,the same substances leading to clinical improvement
in unipolar depression can be used in bipolar depression.
Because of a lower switch risk from depression to hypo-
mania or mania and a proven efficacy, predominantly
SSRIs, monoamine oxidase inhibitors (MAOIs),
67 or
bupropion
68 in combination with mood stabilizers may be
considered as the treatment of choice.
69 Because there is
no uniform definition of “switch,”the switch rates in sci-
entific publications vary widely.Nevertheless,an up to 3-
fold higher switch rate during TCA therapy in compari-
son with SSRIs has been reported.
70Therefore it has been
suggested that all antidepressants,but especially TCAs,
and dually acting antidepressants such as combined sero-
tonin and noradrenaline reuptake inhibitors (SNRIs) are
recommended to be combined with mood stabilizers to
prevent an enhanced switch risk.
In addition, it should be mentioned that for bipolar
depression there is also reasonably good evidence for
monotherapy with the mood stabilizers lithium and lam-
otrigine,as well as with the atypical antipsychotics olan-
zapine and quetiapine.
71 However,there is no evidence
so far that these treatment regimens may be superior in
efficacy when compared with antidepressants.
72
Dysthymia and MDD in combination with dysthymia
Diagnostic criteria for dysthymia and depressive disor-
ders differ in the severity and duration of the symptoms.
Dysthymia is characterized by a chronic depressive syn-
drome of lower intensity of symptoms than severe
depression, although it produces very similar levels of
disabilities.Also,an additional and superimposing major
depressive episode can occur in patients already suffer-
ing from dysthymia,then diagnosed as a “double depres-
sion”or “double major depressive disorder.”The differ-
ential diagnosis of both disorders is difficult if a
dysthymic episode follows a depressive episode,because
the symptoms of dysthymia are then indistinguishable
from the (reduced) symptoms of a depressive disorder
with only partial remission,which should be diagnosed
in this case.Only after a full remission lasting at least 6
months, the subsequent dysthymic symptoms can be
diagnosed as dysthymia.
Because the same antidepressant therapies are efficacious
in both diagnostic entities,the acute treatment plans can
be identical for depressive disorders,dysthymia,and dou-
ble depression.In addition,treatment with certain antipsy-
chotics such as amisulpride
73,74 predominantly at lower
doses, may be of use. Due to the chronic nature of dys-
thymic disorders, an earlier implementation of psy-
chotherapeutic approaches can be of use.In addition,the
treatment goals should be formulated somewhat more
cautiously because dysthymia seems to have a lesser prob-
ability for a complete recovery.
75
Recurrent brief depression
Recurrent brief depression (RBD) is characterized by at
least monthly occurring depressive episodes of short
duration that last only a few days.
76Within DSM-IV-TR,
recurrent brief depression can only be diagnosed as sub-
threshold MDD;within ICD-10 it is a diagnostic category
of recurrent depressive disorder. The combination of
severe depressive disorders and RBD is sometimes called
“combined depression” (CD).
76 The combination of
depressive disorders and RBD shows a relatively high
prevalence. The substantially higher risk for suicidal
ideations in such cases represents a specific concern.
Most trials investigating antidepressant therapies were
designed to judge the therapeutic efficacy in major
depressive disorders.Different study designs are neces-
sary to investigate the combination of depressive disor-
ders and RBD properly. A variety of negative results
after RCTs of SSRIs in the treatment and prophylaxis of
RBD have been published (eg,Montgomery et al
77 and
Angst et al
78),but it was hypothesized that methodolog-
ical problems and highly selected patient samples have
been responsible for for these results.
76 Efficacious treat-
ment algorithms for RBD have not been established
yet.
79
Seasonal affective disorder
Patients suffering from depression recurring on a regu-
lar annual basis during fall or early winter and spring
often show subsequent symptoms of bipolar disorder.In
addition,depressive syndromes often are characterized
by features listed as atypical in DSM-IV-TR.
If depressive symptoms are of moderate severity, sea-
sonal forms of depression are treated like other recurrent
episodes. Bright-light therapy (phototherapy) can be
used as an early augmentation strategy.Because of the
proven efficacy,
80,81 bright-light therapy can even be used
as a monotherapy in case of mild depression during a
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or enhancement of suicidal ideations during photother-
apy has to be taken into account.
82
Other features of MDD influencing course and 
treatment outcome
Atypical depression
There is no clear agreement about the features that
should characterize atypical depression.
83 In French-
speaking countries the term “atypical”depression is used
for a group of patients with psychotic features.According
to DSM-IV-TR in atypical depression at least two of the
criteria summarized in Table IV should be present.
Nevertheless,it was postulated that applying DSM-IV-
TR criteria for atypical depression represents a valid
diagnosis distinct from other forms of depression, but
includes a very heterogeneous patient population.
16Also
the Inventory of Depressive Symptomatology-Clinician
Rating (IDS-C30) is suitable for the diagnosis of atypical
depression including an earlier age at onset, a greater
comorbidity with anxiety symptoms,and greater symp-
tom severity compared with nonatypical depression.
84An
epidemiological study in primary care found a consider-
ably high proportion of depressed patients suffering from
atypical features, suggesting that atypical depression
which may contribute to under-recognition of depression
in primary care.
85 Patients suffering from atypical depres-
sion may have an overall earlier age of onset and a more
chronic course of illness in comparison with patients suf-
fering from depression with melancholic features.
16
Nevertheless,those patient groups are also characterized
by a high longitudinal association,ie,an overlap of symp-
toms during the time course of depression: transitions
from atypical to melancholic and to nonmelancholic
types of depression are described.
86
Empirical data support the hypothesis that MAOIs and
SSRIs represent a first-line treatment option which is supe-
rior to other pharmacological treatments.
17,87,88 Due to the
need of specific precautions,irreversible MAOIs are not
recommended in some countries as a first-line treatment.
Circadian rhythm disturbances
Sleep-wake rhythm disturbances, including hypo- or
insomnia,are present in a majority of depressed patients
suffering from difficulties in falling asleep,interrupted
and shortened sleep during the night,and early awaken-
ing in the morning.In addition,hypersomnia character-
izes most patients suffering from atypical depression (see
above).They are rated as criteria for MDD in ICD-10,as
accessory symptoms in DSM-IV-TR,as depressive symp-
toms within the HAM-D17 scale,and are included in the
abovementioned CORE scale for depressive core sym-
toms.
14 In addition specific sleep EEG patterns,such as
reduced slow-wave sleep and shortened REM sleep
latency,characterize MDD especially in the presence of
melancholic symptoms.
13 Sleep EEG abnormalities are in
addition strongly influenced by age and gender of the
depressed patients.
89
From a clinical point of view the use of antidepressants
with antihistaminergic and therefore sedating properties,
eg,some TCAs or noradrenergic and specific serotoner-
gic antidepressants (NaSSAs) or the use of nonsedating
antidepressants in combination with sleep-inducing treat-
ments,are useful.In this case,nonbenzodiazepine hyp-
notics, benzodiazepines, or sedating atypical antipsy-
chotics which at the same time can augment the
antidepressant treatment are suitable. Mirtazapine
monotherapy significantly improves sleep parameters in
addition to its antidepressant effects
90 without the
neceessity of additional hypnotic substances.
Unfortunately,initial somnolence and dizziness,together
with increased appetite and consecutive weight gain in
the long term
91 may represent antihistaminergic side
effects which often reduce the patients’ compliance and
may sometimes even facilitate the development of a
metabolic syndrome.While most antidpressants are mod-
ifying sleep profiles by suppressing rapid eye movement
(REM) sleep,the only dopamine (D)2 and serotonin (5-
HT)2 antagonistic acting substance with antihistaminer-
gic sedating properties without REM suppression is the
TCA trimipramine.
92
An interesting future perspective may therefore be the use
of the MT1/MT2 agonistic and 5-HT2c antagonistic acting
antidepressant agomelatine. In healthy older men no
effects on normal sleep patterns were found,
93 while in
patients suffering from MDD in a pilot dose-finding
study
94,95 symptoms related to sleep disturbances such as
difficulties in falling asleep,interrupted sleep,shortened
sleep, early awakening, and drowsiness decreased sub-
stantially,leading to a normalization of sleep/wake rhythms
without direct sedation and without REM sleep suppres-
sion,indicating that agomelatine contributes to a normal-
ization of disrupted circadian rhythms in depression.
Pharmacological aspects
316Depressive syndrome with comorbid pain conditions
Depressive disorders and predominantly chronic pain are
frequent comorbid conditions. Approximately 70% of
patients with major depression present physical com-
plaints.
96,97 Severe pain caused by somatic diseases comor-
bid with depression makes the treatment of depression dif-
ficult. Somatoform disorders, fibromyalgia, and similar
conditions characterized by pain are often accompanied by
depressed mood.Effective treatment of neuropathic pain
requires the application of antidepressants with a mixed
serotonergic and noradrenergic mode of action such as the
TCA amitriptyline.
98 More recently,newer antidepressants
have been shown to be useful in the treatment of pain con-
ditions with and without comorbid depression.The efficacy
of various pharmacodynamic classes such as SSRIs,NARI,
NaSSAs,
99 and SNRIs
100,101 has been shown.It seems plausi-
ble that antidepressants with both serotonergic and nora-
drenergic properties are particularly effective in the treat-
ment of pain and painful physical symptoms. Higher
remission rates in these subgroups of depressed patients
have been discussed recently.
102Antidepressants are now
seen by many as an essential supplement in a variety of
therapeutic regimes for pain control.
Depressive syndrome in adjustment disorders
Due to the fact that the symptoms of adjustment disor-
ders and depressive disorders may be identical,and due
to the fact that depressive episodes often occur after
exposure to severe stress,it is justified to offer the same
therapeutic regimes to patients suffering from adjust-
ment disorders as to patients suffering from depressive
disorders. This is especially true during the period of
acute treatment.Controlled efficacy trials in adjustment
disorders are rare,but both clinical experience and ret-
rospective studies
103 suggest no crucial difference between
depression and adjustment disorder in response rates to
treatment.On the contrary,some authors also suggested
lower response rates for biological treatments such as
ECT in depressive syndromes caused by adjustment dis-
orders.
13 Nevertheless,the use of psychosocial therapies
in adjustment disorders may begin earlier and be more
intense in comparison with patients suffering from severe
MDD and melancholia.
Summarizing the symtomatology of depression in those
patients,a broad overlap between the abovementioned
three subgroups can be suggested.
Because the positive diagnosis of the core symptoms of
depression may lead to clinical consequences for indi-
vidual treatment plans,it would be of use to integrate all
mentioned concepts in the upcoming new versions of the
diagnostic systems,DSM-V and ICD-11.
Conclusion
Core symptoms of depression according to diagnostic
systems and rating scales are a combination of psycho-
logical symptoms such as depressed mood (sadness or
feelings of emptiness are synonymously used),anhedo-
nia, diminished interest or pleasure, and suicidality in
combination with somatic symptoms such as disturbed
sleep and appetite.Furthermore,psychomotor and cog-
nitive disturbances consitute further core symptoms.
Most diagnostic subdivisions of depressive states accord-
ing to diagnostic systems or rating scales,eg,the use of
concepts such as melancholic depression, endogenous
depression,or the subdivision according to the need for
hospitalization or to the severity of disease lead to a
patient group of predominantly severely depressed
patients suffering from most of the core symptoms,
together with the clinical characteristics of a cyclic unipo-
lar or bipolar course,lower placebo response rates,higher
response rates to ECT,to antidepressant treatments with
dually or mixed modes of action,or to lithium augmen-
tation.In addition,higher rates of biological characteris-
tics such as HPA-axis hyperactivity and specific EEG
patterns have been shown in this patient group. ❏
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